for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Syngene International Ltd

SYNN.NS

Latest Trade

573.15INR

Change

-4.45(-0.77%)

Volume

256,374

Today's Range

567.50

 - 

582.25

52 Week Range

368.00

 - 

644.55

As of on the National Stock Exchange of India ∙ Minimum 15 minute delay

Pricing

Previous Close
577.60
Open
579.80
Volume
256,374
3M AVG Volume
9.46
Today's High
582.25
Today's Low
567.50
52 Week High
644.55
52 Week Low
368.00
Shares Out (MIL)
397.95
Market Cap (MIL)
228,086.90
Forward P/E
52.68
Dividend (Yield %)
--

Next Event

Q1 2022 Syngene International Ltd Earnings Release

Latest Developments

More

Syngene International Ties Up With HiMedia Laboratories To Manufacture ELISA Test Kits For COVID-19

Syngene International Appoints Jonathan Hunt As CEO

Syngene International Appoints Sibaji Biswas As CFO

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Syngene International Ltd

Syngene International Limited is a contract research company. The Company is engaged in providing contract research and manufacturing services in early-stage drug discovery and development to pharmaceutical and biotechnology companies. Its services include discovery chemistry and biology services, toxicology, pharmaceutical development, process development/manufacture of intermediates, active pharmaceutical ingredients and bio-therapeutics. Its services encompass integrated, discovery and development services for novel molecular entities (NMEs) across industrial sectors, including pharmaceutical, biopharmaceutical and biotechnology, among others. It specializes in conducting discovery (from hit to candidate selection), development (including pre-clinical and clinical studies, analytical and bio-analytical evaluation, and stability studies) and manufacturing (scale-up, pre-clinical and manufacturing supplies). It serves clients ranging from multinational corporations to start-ups.

Industry

Biotechnology & Drugs

Contact Info

+91.80.67758781

http://www.syngeneintl.com/

Executive Leadership

Kiran Mazumdar Shaw

Executive Chairman of the Board, Managing Director

Jonathan Hunt

Chief Executive Officer, Whole Time Director

M. B. Chinappa

Chief Financial Officer

Manoj Nerurkar

Chief Operating Officer

Priyadarshini Mahapatra

Compliance Officer, Company Secretary

Key Stats

2.60 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, INR)

2019

18.3K

2020

20.1K

2021

21.8K

2022(E)

25.4K
EPS (INR)

2019

8.360

2020

8.540

2021

8.990

2022(E)

10.879
Price To Earnings (TTM)
56.64
Price To Sales (TTM)
10.44
Price To Book (MRQ)
8.07
Price To Cash Flow (TTM)
33.57
Total Debt To Equity (MRQ)
31.65
LT Debt To Equity (MRQ)
21.89
Return on Investment (TTM)
12.70
Return on Equity (TTM)
8.95

Latest News

Latest News

Syngene targets delivering 500,000 vials of remdesivir in India as COVID-19 surges

India's Syngene International Ltd aims to supply half-a-million vials of COVID-19 drug remdesivir through its local distribution partners next month, its top executive said, as the country faces shortages of the medicine amid a second wave.

BRIEF-Syngene International Ties Up With HiMedia Laboratories To Manufacture ELISA Test Kits For COVID-19

* TIES UP WITH HIMEDIA LABORATORIES TO MANUFACTURE ELISA TEST KITS FOR COVID-19 Source text: (https://bit.ly/2AtfQ2f) Further company coverage:

BRIEF-Syngene International Temporarily Halts Activities At Facilities

* TEMPORARY SUSPENSION OF RESEARCH ACTIVITIES AT FACILITIES AT BANGALORE SEZ AND HYDERABAD Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up